Federal award (DEFINITIVE CONTRACT, fiscal year 2023)
Recipient: MINISTRY OF DEFENCE
Awarding agency: Department of Defense / Defense Threat Reduction Agency
Funding agency: Department of Defense / Defense Threat Reduction Agency
Period of performance: 2024-06-10 to 2026-06-09
Current total value of award: $4346947
Description: GENERATION OF A NOVEL ANTIBODY-ANTIBIOTIC CONJUGATE AS A COMBINATION THERAPY PLATFORM TO TREAT MELIOIDOSIS OR PLAGUE.